Beijing TsingPAI Technology Co., Ltd. is a high-end medical-device and life-health technology company spun off from Tsinghua University research. With the mission of "precision visualization for better health", we build domestically controllable instrument platforms for ultrasound brain-computer interfaces and precise neuromodulation.
TsingPAI focuses on frontier technology platforms including ultrasound brain-computer interfaces, focused-ultrasound neuromodulation, focused-ultrasound BBB-opening drug delivery, and photoacoustic / ultrasound / thermoacoustic multimodal imaging — with independent R&D capability spanning core components, ultrasound TX/RX platforms, phased-array transducers, control software, algorithms and complete instruments.
The team originates from Tsinghua University and was incubated with support from the Tianjin Institute of Electronics and Information Technology (Tsinghua), the Tsinghua-Fuzhou Institute of Data Technology, Tsinghua Straits Research Institute (Xiamen) and Zhongguancun Zhiyou Research Institute. The company advances productization and clinical translation around brain-disease treatment, drug delivery, neurofunctional rehabilitation and advanced research instruments.
Beijing TsingPAI Technology Co., Ltd. was founded as a Tsinghua research spin-off, focusing on photoacoustic imaging systems and core components.
Angel round completed (FreesFund, Hetang Exploration, Shuimu Dongfang); the self-developed photoacoustic DAQ entered multiple universities and research institutes across China.
Pre-A round completed (GTJA Healthcare Fund / Gaotejia, Xiamen Hi-Tech Investment, Chengmei Digital Intelligence, etc.); the whole-brain photoacoustic PATTERN work was published in Nature Communications; the USP ultrasound TX/RX platform was released and imaging systems upgraded to photoacoustic / ultrasound dual modality.
The 256-channel phased-array ultrasound neuromodulation system entered delivery; the 3D microvascular imaging system for diabetic foot / PAD advanced toward registration; commercialization accelerated.
The image-guided multi-channel transcranial focused ultrasound neuromodulation system (tFUS-Neuro256/512) was released and delivered; the Pre-A+ round is in progress; platform capabilities around ultrasound BCI and BBBO drug delivery continue to build.
TsingPAI has completed angel and Pre-A rounds, with the Pre-A+ round in progress. Investors and industry partners are welcome to reach out.
TsingPAI has built a diversified product portfolio spanning research instruments, core components, customized systems and ultrasound neuromodulation platforms, with steady commercialization progress. Detailed operating data and financing materials are available on request. For investment cooperation, please contact sales@tsingpai.com and we will provide company and financing materials.
High-value focused-ultrasound neuromodulation and photoacoustic imaging systems benchmarked against imported alternatives.
Technical support services for focused-ultrasound neuromodulation and photoacoustic imaging experiments, including on-site support and protocol consulting.
Photoacoustic imaging modules, DAQ / USP TX/RX platforms, lasers, transducers and other core components.
Custom product development around project-specific needs — from components to complete instruments.
Based on the multimodal functional imaging platform and the focused-ultrasound neuromodulation platform, TsingPAI collaborates with university scientists, young PIs and hospital clinicians on applied research in neuromodulation, BBBO, microcirculation imaging and neurorehabilitation — forming diverse cooperation spanning instruments, technical services, joint projects and prototype development.
Research collaboration, business cooperation or joining the team — we would love to talk.
